Sellas life sciences group, inc. (SLS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Cash flows from operating activities:
Net loss

-4,143

-7,419

-4,202

-3,134

-4,537

-13,323

-290

-6,062

-7,995

-8,785

-4,455

-5,913

-4,601

-

-

-

-13,102

-

-6,370

-13,474

-8,306

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-19,941

-2,536

-

-9,287

-9,597

-9,293

-

-6,261

-196

-24,761

Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-92

30

59

6

-197

123

83

98

-254

-121

229

232

118

127

39

2

2

3

2

42

Non-cash accretion of debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

568

645

67

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

0

19

95

20

-258

0

258

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Deferred income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,115

1,158

1,541

-2,762

-1,052

0

0

0

Non-cash rent expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Accretion and receipt of bond discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Non-cash stock-based compensation

145

147

115

126

185

111

137

125

22

-607

1,267

1,572

937

-1,476

552

622

656

597

575

388

371

788

742

1,513

1,623

963

729

251

364

326

447

194

427

Change in fair value of warrants potentially settleable in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Fair value of common stock issued in exchange for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-41

41

-

-

-

-

-

-

-

-

-

-

-

-

-

96

98

148

Fair value of common stock issued in connection with litigation settlements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

185

Change in fair value of common stock warrants

35

28

-45

958

195

-38

2,241

1,218

1,881

0

0

0

0

-

3,652

14,392

-3,872

2,143

2,133

-4,266

1,151

3,382

6,735

-3,353

9,792

-36,866

-1,614

-518

-5,003

1,124

-267

-29,902

18,270

Fair value of common stock issued in exchange for licensing rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Change in fair value of contingent consideration

-138

-76

-28

-95

-387

993

-162

-452

-3,411

0

0

0

0

-

-145

5,497

-170

440

307

83

-321

229

597

-490

-166

-367

-172

56

-443

-351

-471

-2,392

844

Loss on settlement of liability-classified warrants

-

-

-

-

-

0

0

42

685

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

686

-2,217

-

1,543

0

0

-

-

-

-

Inventories

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

75

-28

-

73

352

0

-

-

-

-

Prepaid expenses and other assets

1,350

-404

165

13

302

-750

-66

-18

622

-70

0

111

-114

858

-240

277

-418

219

282

-226

-30

730

9

413

-74

-369

83

174

-325

-266

41

635

-14

Litigation settlement insurance recovery

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-1,700

-20,000

21,700

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Litigation settlement payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,100

100

-20,000

24,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-1,303

239

36

-1,146

883

-3,483

-4,861

648

-240

7,989

680

-3,888

3,585

-

-379

254

-578

359

177

-850

25

-75

678

462

-1,086

17

-202

-31

147

-234

504

-55

426

Due to former parent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Accrued expenses and other current liabilities

-283

-333

323

374

-1,412

-2,464

683

-1,698

1,197

-2,459

85

3,838

-3,838

3,303

-884

661

-1,250

-2,037

-176

505

-1,885

1,579

-657

2,096

1,026

836

481

1,054

440

16

534

-247

-452

Net cash used in continuing operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,172

-7,847

-9,741

-10,973

-8,393

-8,939

-10,497

-

-

-

-

-

-

-

-

-

-

-

-

Loss from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,587

-2,889

-3,391

-8,872

-11,657

-2,186

-2,231

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities attributable to discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-551

755

84

-12

-2,519

735

-1,172

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in discontinued operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,036

-3,644

-3,475

-4,311

-1,067

-2,921

-1,059

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-6,831

-4,176

-3,820

-4,656

-4,991

-4,555

-14,165

-6,299

-5,403

-1,742

-2,395

-3,049

-3,803

25,065

-12,208

-11,491

-13,216

-15,284

-9,460

-11,860

-11,556

-10,734

-11,115

-12,972

-8,048

-8,492

-7,983

-7,123

-5,331

-5,178

-4,165

-6,745

-4,885

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

100

-2

0

1

-

0

0

0

Cash paid for acquisition of Zuplenz rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

10,086

-

-

-

-

Cash paid for acquisition of GALE-401

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

100

0

305

2,010

0

0

0

0

-

-

-

-

Purchase of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Cash received in Apthera acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Maturities of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Cash paid for purchase of equipment and furnishings

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

6

72

47

16

18

9

19

7

22

-234

104

450

0

-

0

0

0

Net cash used in continuing investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-6

-72

-248

-16

-18

-

-

-

-

-

-

-

-

-

-

-

-

Selling costs paid for sale of commercial assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,050

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for commercial assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

34

500

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in discontinued investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-1,050

11,283

0

-34

-500

-

-

-

-

-

-

-

-

-

-

-

-

Disposal of equipment and furnishings

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Cash paid for lease deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Cash transferred with the RXi spin-off

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

87

0

Net cash used from investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

971

0

0

-1,056

11,211

-248

-50

-518

-109

-3,075

-312

-2,032

-2,804

720

131

-10,087

0

0

-87

0

Cash flows from financing activities:
Proceeds from issuance of Series A convertible preferred stock and common stock warrants, net of issuance costs

-

-

-

-

-

0

0

4,319

5,328

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net of offering costs

5,988

2,319

-129

13,781

0

-

-

-

-

-

-

-

-

-

11,615

0

20,189

0

0

5,295

42,121

10,704

0

0

0

-

-

-

-

22,441

72

13,480

385

Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock recorded as issuance cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,276

0

5,590

0

0

0

10,296

-

-

-

-

-

-

-

-

7,286

0

0

0

Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock

-

-

-

-

-

-

-

-

1,968

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of interest and principal on long-term debt through issuance of common stock

-

-

-

-

-

134

-114

2,070

1,631

0

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collection of stock subscription receivable

-308

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for repurchase of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

266

0

Cash paid for repurchase of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

247

14

-

-

-

-

0

272

11

4,059

558

9

0

0

21

0

0

0

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

132

-26

10,611

6,995

190

576

54

36

288

4,148

1,236

Net proceeds from exercise of warrants

4

-

318

1,050

2,230

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from common stock issued in connection with ESPP

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6

-38

-54

0

-78

39

Proceeds from common stock issued in connection with Employee Stock Purchase Plan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

0

78

0

199

0

110

0

172

38

53

-

-

-

-

-

-

-

-

Net proceeds from issuance of RXi convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-1,000

500

Change in restricted cash related to debt principal paid in common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-22,141

0

23,641

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on long-term debt

-

-

-

-

-

76

6,936

0

589

120

1

352

0

-

0

3,749

1,030

1,009

988

967

947

858

901

4

3

-

-

-

-

-

-

-

-

Principal payments on long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Repayments of capital lease obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

17

0

-

0

3

7

Net cash provided by financing activities

6,300

2,319

189

14,831

2,230

-76

14,252

4,208

4,739

-120

-1

5,655

0

-16,255

17,132

-3,628

19,251

-1,009

-759

4,329

41,284

9,846

-325

19

14,720

7,687

37,740

10,430

92

22,562

360

17,359

2,153

Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents

-531

-1,857

-3,631

10,175

-2,761

-4,631

87

-2,091

-664

10,296

-2,396

2,606

-3,803

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

9,781

4,924

-15,119

4,979

-5,082

-10,467

-7,581

29,210

-997

-14,515

-13,265

4,640

-3,609

30,477

3,438

-15,326

17,384

-3,805

10,527

-2,732

Supplemental disclosure of cash flow information:
Cash received during the periods for interest

24

31

55

18

14

20

87

45

34

0

-1

1

0

-

35

28

21

6

10

0

2

2

3

5

5

-

-

-

1

1

-1

0

1

Cash paid during the year for interest

-

-

-

-

-

0

139

72

110

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid during the periods for interest

-

-

-

-

-

-

-

-

-

-

-

0

0

-

30

494

112

104

125

146

166

168

209

212

211

352

248

-53

0

1

36

-37

1

Supplemental disclosure of non-cash investing and financing activities:
Debt issued in connection with warrant exchange agreements

-

-

-

-

-

0

0

78

888

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating right of use asset and current and non-current liability

123

-1

0

550

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of warrant liabilities upon exchange for shares of common stock

-

-

-

-

-

0

0

0

285

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impact of anti-dilution protection on liability-classified warrants

0

0

0

70

173

0

491

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering expenses in accounts payable and accrued expenses and other current liabilities

25

-

-129

365

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net liabilities distributed to common stock holders in the RXi spin-off, net of cash transferred

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

2,246

0

Fair value of shares mandatorily redeemable for cash upon exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Reclassification of warrant liabilities upon exercise

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

278

46

-

-

-

-

6

0

212

26,808

12,179

863

1,083

124

102

20,890

-10,149

0

Stock issued

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Common stock issued in settlement of contingent purchase price consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,579

0

Allocation of management expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Equipment and furnishings exchanged for common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Equipment and furnishings acquired through capital lease

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Non-cash lease deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Value of restricted stock units and common stock issued in lieu of cash bonuses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Change in fair value of marketable securities before settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,229

1,557

3,923

-7,031

-2,678

0

0

0

Issuance of common stock in settlement of GALE-401 milestone

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Fair value of shares issued to acquire Zuplenz rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-5,000

0

0

0

0

Fair value of shares issued to acquire NeuVax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0